The Cost-effectiveness analysis of HMGA2 prognostic test for AML is now published

Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukemia in a Canadian setting is now available in Applied Health Economics and Health Policy.

Read our latest publication on Mubritinib

Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia is now published in Cancer Cell.